Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01368445 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Safety and Efficacy of a Nasal Spray to Treat Seasonal Allergies
A Phase 3 study, sponsored by Meda Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 617
- Enrollment target
NCT01368445: Completed Phase 3 study, sponsored by Meda Pharmaceuticals.
NCT01368445 is a Phase 3 study that has completed, run by Meda Pharmaceuticals. The registered enrollment target is 617 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (20% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01368445, a Phase 3 study, has completed, sponsored by Meda Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 617 participants
- Enrollment target
Study Summary
The Purpose of this study is to evaluate the safety and efficacy of MP03-36 (0.15% azelastine hydrochloride)at dosages of 2 sprays per nostril once daily and 2 sprays per nostril twice daily in patients with seasonal allergic rhinitis.
Interventions
- DRUG azelastine hydrochloride 0.15% Nasal Spray
- DRUG azelastine hydrochloride 0.15% and Placebo
- DRUG Azelastine 0.1%, Nasal Spray
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 617 participants |
| Start Date | 2006-08 |
| Est. Completion | 2008-04 |
| Phase | Phase 3 |
What the finished NCT01368445 record still lists
NCT01368445 is an interventional study that assigns participants to a tested intervention. The registered 617 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (20% lower).
The record links to 0 conditions, and to 3 interventions - of which azelastine hydrochloride 0.15% Nasal Spray is the first listed.
NCT01368445 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01368445 about?
NCT01368445 is a clinical study titled "A Study to Evaluate the Safety and Efficacy of a Nasal Spray to Treat Seasonal Allergies". The Purpose of this study is to evaluate the safety and efficacy of MP03-36 (0.15% azelastine hydrochloride)at dosages of 2 sprays per nostril once daily and 2 sprays per nostril twice daily in patients with seasonal allergic rhinitis.
What is the current status of trial NCT01368445?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 617 participants. The study started on 2006-08. Estimated completion is 2008-04.
What interventions are being tested in trial NCT01368445?
The interventions under investigation include: azelastine hydrochloride 0.15% Nasal Spray (DRUG), azelastine hydrochloride 0.15% and Placebo (DRUG), Azelastine 0.1%, Nasal Spray (DRUG).
Who is sponsoring clinical trial NCT01368445?
This trial is sponsored by Meda Pharmaceuticals, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01368445's enrollment target sits among peer trials
617 592nd of 2000 higher than 1,408 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02610179 · 617 participants · NA
Strawberry Candy Twists as an Alternative Screen for Gestational Diabetes: A Prospective Trial
- NCT05672927 · 618 participants · Phase 4
Comparing Immune Response of 2 vs 3 HPV Doses (27-45 Years Old)
- NCT06220721 · 618 participants · NA
Reducing the Risk of Chronic Hypertension and Improving Vascular Function Following Preeclampsia
- NCT04813185 · 616 participants · NA
Preventing Retaliatory Gun Violence in Violently Injured Adults
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia